Eric Padron
Tampa
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Eric Padron
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms - Leukemia
Myelodysplastic syndromes/neoplasms (MDS) are clonal stem cell disorders characterized by bone marrow (BM) dysplasia and risk of progression to acute myeloid leukemia (AML) [1]. Treatment decisions are conventionally based on peripheral blood counts, BM blast percentage, and cytogenetic profile, integrated into the International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R) [2, 3].
Modeling the evolutionary dynamics of clonal hematopoiesis - Nature Genetics
Abstract Clonal hematopoiesis (CH) results from the acquisition and expansion of somatic mutations in hematopoietic stem and progenitor cells and is associated with age-related clinical sequelae, including an increased risk for cardiovascular disease, myeloid neoplasms and complications related to cancer therapy. Chemotherapy and radiation can accelerate CH expansion and further elevate the risk of adverse events, including cardiotoxicity and therapy-related myeloid neoplasms.
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes - Leukemia
|
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping myelodysplastic (MD) and myeloproliferative (MP) features [1, 2]. Somatic TET2 mutations (TET2MT) are present in 40–60% of CMML patients and are associated with improved overall (OS) and acute leukemia free survival (LFS) [3, 4]. This is due, in part, to a protective effect of TET2MT in the context of adverse ASXL1MT and a higher response rate to hypomethylating agents (HMA) [4, 5].
By Clifford M. Csizmar, Mark Gurney, Saubia Fathima, Rashmi Kanagal-Shamanna, Sanam Loghavi, Kelly S. Chien, Danielle Hammond, Courtney DiNardo, Tapan M Kadia, Farhad Ravandi-Kashani, Naveen Pemmaraju, Koji Sasaki, Hassan B. Alkhateeb, Kebede H. Begna, Mehrdad Hefazi Torghabeh, Abhishek A. Mangaonkar, Antoine Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Rami S. Komrokji, Zhuoer Xie, David A Sallman, Eric Padron, Guillermo Montalban-Bravo
|
Nature
Verified
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm - Leukemia
Abstract Myelodysplastic neoplasms (MDS) are stem cell disorders characterized by ineffective hematopoiesis and risk of transformation to acute myeloid leukemia (AML). Chromosomal alterations are frequent in MDS, with interstitial deletion of chromosome 5q (del(5q)) being the most common. Lenalidomide is the current first-line treatment for del(5q) MDS and its efficacy relies on degradation of CK1α which is encoded by the CSNK1A1 gene located in the commonly deleted region (CDR) of chromosome 5q.
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study - Leukemia
Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy with overlapping features of myelodysplastic neoplasm (MDS) and myeloproliferative neoplasms characterized by peripheral blood monocytosis [1]. There is a predisposition for transformation to acute myeloid leukemia (AML), termed CMML with blast transformation (CMML-BT) [2, 3].
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML) - Leukemia
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 265,23 € per year only 22,10 € per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Additional access options: Log in Learn about institutional subscriptions Read our FAQs Contact customer support Data availability Please email the...
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes - Leukemia
Abstract The Molecular International Prognostic Scoring System (IPSS-M) is a novel risk stratification model for myelodysplastic syndromes (MDS) that builds on the IPSS and IPSS-R by incorporating mutational data. The model showed improved prognostic accuracy over the IPSS-R across three endpoints: overall survival (OS), leukemia-free survival (LFS) and leukemic transformation.
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms - Leukemia
This is a preview of subscription content, access via your institution Access options Subscribe to Journal Get full journal access for 1 year $119.00 only $9.92 per issue All prices are NET prices. VAT will be added later in the checkout. Tax calculation will be finalised during checkout. Buy article Get time limited or full article access on ReadCube. $32.00 All prices are NET prices.
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes - Leukemia
|
This is a preview of subscription content, access via your institution Access options Subscribe to Journal Get full journal access for 1 year $119.00 only $9.92 per issue All prices are NET prices. VAT will be added later in the checkout. Tax calculation will be finalised during checkout. Buy article Get time limited or full article access on ReadCube. $32.00 All prices are NET prices.
By Jan Philipp Bewersdorf, Mikkael Sekeres, Uwe Platzbecker, Sanam Loghavi, Jacqueline Boultwood, Rafael Bejar, Hetty Carraway, Elizabeth A. Griffiths, Stephanie Halene, Robert P Hasserjian, Christopher S Hourigan, Nina H. Kim, Rami S. Komrokji, Richard Little, Eric Padron, Mrinal Patnaik, David A Sallman, Guillermo Sanz, Daniel T. Starczynowski, Justin Taylor, Zhuoer Xie, Mina L. Xu, Michael Savona, Ravi Majeti, Stephen D. Nimer
|
Nature
Verified
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms - Leukemia
|
Abstract The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition.
By Joseph Khoury, Eric Solary, Yassmine Akkari, Jane F. Apperley, Rafael Bejar, Lambert Busque, Weina Chen, John Choi, Isabel Colmenero, Jean-François Emile, Torsten Haferlach, Shimin Hu, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Christian P. Kratz, Sanam Loghavi, Kikkeri N. Naresh, Yasodha Natkunam, Eric Padron, Nikhil V. Patkar, Uwe Platzbecker, Anna Schuh, Prashant Tembhare, Jeffrey W. Tyner, Srdan Verstovsek, Wei Qing Wang, Wenbin Xiao, Andreas Hochhaus Verified, Emiko Takahashi
|
Nature
Verified
Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?
CORRESPONDENCE Somedeb Ball MD, Corresponding Author Somedeb Ball MD somedeb.ball@moffitt.org orcid.org/0000-0002-1754-1204 Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Correspondence Dr. Somedeb Ball, MD, Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL- 33612, Email: somedeb.ball@moffitt.org Search for more papers by this author Akriti G.
Acquisition of IDH2 Mutations in Relapsed/Refractory AML Is Associated with Worse Patient Outcomes
ORIGINAL ARTICLE Amy Song, New Jersey Medical School, Rutgers University, Newark, NJ, USA Search for more papers by this author Omar Altabbakh, Nova Southeastern University, Clearwater, FL, USA Search for more papers by this author David A. Sallman, Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Search for more papers by this author Eric Padron, Department of Malignant Hematology, H.
Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia
References 1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. CAS PubMed Article Google Scholar 2. Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016;174:382–96.
Chronic myelomonocytic leukemia diagnosis and management
Abstract Chronic myelomonocytic leukemia (CMML) is a rare, heterogeneous myeloid malignancy classified as a myelodysplastic syndromes/myeloproliferative neoplasm (MDS/MPN) overlap syndrome by the World Health Organization (WHO). Its initial presentation can be incidental or associated with myelodysplastic or myeloproliferative symptoms and up to 20% of patients harbor a concurrent inflammatory or autoimmune condition. Persistent monocytosis is the hallmark of CMML but diagnosis can be challenging.
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study
Summary Background Approval of hypomethylating agents in patients with chronic myelomonocytic leukaemia is based on trials done in patients with myelodysplastic syndromes. We aimed to investigate whether hypomethylating agents provide a benefit in subgroups of patients with chronic myelomonocytic leukaemia compared with other treatments. Methods For this retrospective cohort study, data were retrieved between Nov 30, 2017, and Jan 5, 2019, from 38 centres in the USA and Europe.
Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome
Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome Ibraahim Badaat1, Sabbir Mirza1, Eric Padron2, David Sallman2, Rami Komrokji2, Jinming Song3, Mohammad O Hussaini3 1 College of Arts and Sciences, University of South Florida, Tampa, Florida, USA 2 Division of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA 3 Hematopathology, H Lee Moffitt Cancer Center and Research Institute,...
Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome
Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome Ibraahim Badaat1, Sabbir Mirza1, Eric Padron2, David Sallman2, Rami Komrokji2, Jinming Song3, Mohammad O Hussaini3 1College of Arts and Sciences, University of South Florida, Tampa, Florida, USA 2Division of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA 3Hematopathology, H Lee Moffitt Cancer Center and Research Institute, Tampa,...
Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity
In many cancers, there still exists a critical need to understand the mechanisms of the evolution of therapy resistance.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Eric
Contact Eric, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack